NEW YORK ─ Ortho Clinical Diagnostics said after the market close on Wednesday that it has priced an initial public offering of 76,000,000 ordinary shares at $17 per share for anticipated gross proceeds of $1.29 billion.
Shares of the Raritan, New Jersey-based pure-play diagnostics firm are expected to begin trading Thursday on the Nasdaq under the symbol OCDX.
Ortho has granted the IPO underwriters a 30-day option to purchase up to 11,400,000 additional shares at the initial public offering price less underwriting discounts and commissions.